BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 199 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $13,226,292 | -2.2% | 1,152,116 | +7.4% | 0.00% | -25.0% |
| Q3 2022 | $13,521,262 | -35.6% | 1,073,116 | -45.9% | 0.00% | -20.0% |
| Q2 2022 | $21,005,162 | +62.4% | 1,985,365 | +149.6% | 0.01% | +66.7% |
| Q1 2022 | $12,935,285 | +30.1% | 795,528 | +10.8% | 0.00% | +50.0% |
| Q4 2021 | $9,940,000 | -13.2% | 717,674 | -9.9% | 0.00% | -33.3% |
| Q3 2021 | $11,448,000 | +322.6% | 796,674 | +364.9% | 0.00% | +200.0% |
| Q2 2021 | $2,709,000 | +55.4% | 171,351 | 0.0% | 0.00% | – |
| Q1 2021 | $1,743,000 | -33.3% | 171,351 | -51.1% | 0.00% | -100.0% |
| Q4 2020 | $2,613,000 | -26.3% | 350,760 | -66.0% | 0.00% | 0.0% |
| Q3 2020 | $3,545,000 | +36.9% | 1,032,093 | +89.9% | 0.00% | 0.0% |
| Q2 2020 | $2,590,000 | – | 543,493 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |